ADC Therapeutics Congress Data Presentations
Browse through posters and presentations and learn about upcoming congress dates.
Filter by:Clear All
Filter by Congress, Product, and Year
Display upcoming eventsCongress
Product/compound
Year
PPLC 2024 | POSTERJul 15–19, 2024
Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Codosed With a CD20/CD3 T-cell Bispecific (Epcoritamab) in Diffuse Large B-cell Lymphoma
Presentation will be accessible soon.
PPLC 2024 | POSTERJul 15–19, 2024
Phase 1b Open-Label Study Of Loncastuximab Tesirine In Combination With Other Anticancer Agents In Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (LOTIS-7)
Presentation will be accessible soon.
ASCO 2024 | POSTERMay 31–Jun 4, 2024
LOTIS-5, an Ongoing, Phase 3, Randomized Study of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
Presentation will be accessible soon.
AACR 2024 | POSTERApr 5–10, 2024
Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b
Presentation will be accessible soon.
AACR 2024 | POSTERApr 5–10, 2024
Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6
Presentation will be accessible soon.
AACR 2024 | POSTERApr 5–10, 2024
Phase 1b Trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas
Presentation will be accessible soon.
AACR 2024 | POSTERApr 5–10, 2024
Preclinical anti-tumorigenic evaluation of AXL antibody-drug-conjugate in an adenoid cystic carcinoma cell line xenograft model
Independent
Independent
Presentation will be accessible soon.
AACR 2024 | POSTERApr 5–10, 2024
Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL
Presentation will be accessible soon.
Tandem 2024 | POSTERFeb 21–24, 2024
Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Following Chimeric Antigen T Cell Therapy in the US
Presentation will be accessible soon.
Tandem 2024 | POSTERFeb 21–24, 2024
Real-World Treatment Patterns and Outcomes of Patients with Large B-Cell Lymphoma (LBCL) Who Received Loncastuximab Tesirine Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Presentation will be accessible soon.
ASH 2023 | ORAL PRESENTATIONDec 9–12, 2023
Limited duration loncastuximab with rituximab induces high complete response rate in high-risk relapsed/refractory follicular lymphoma – A phase 2 study
Presentation will be accessible soon.
ASH 2023 | POSTERDec 9–12, 2023
Loncastuximab Tesirine Demonstrated Substantial Single-agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Presentation will be accessible soon.
ASH 2023 | POSTERDec 9–12, 2023
Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Presentation will be accessible soon.
ASH 2023 | POSTERDec 9–12, 2023
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)
Presentation will be accessible soon.
ASH 2023 | POSTERDec 9–12, 2023
Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases
Presentation will be accessible soon.
ASH 2023 | POSTERDec 9–12, 2023
A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy
Presentation will be accessible soon.
ACCP 2023 | POSTERSep 10–12, 2023
A Clinical Quantitative Systems Pharmacolgy Framework Describing Loncastuximab Tesirine Distribution and the Exploration of Patient Outcomes From the LOTIS-2 Clinical Trial in Patients with B-cell Lymphomas
Presentation will be accessible soon.
SOHO 2023 | POSTERSep 6–9, 2023
Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
Presentation will be accessible soon.
SOHO 2023 | POSTERSep 6–9, 2023
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7)
Encore ASCO 2023
Encore ASCO 2023
Presentation will be accessible soon.
ICML 2023 | ORAL PRESENTATIONJun 13–17, 2023
Long-Term Responses With Loncastuximab Tesirine: Updated Results From LOTIS-2, the Pivotal Phase 2 Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
EHA 2023 Encore
EHA 2023 Encore
Presentation will be accessible soon.
EHA 2023 | POSTERJun 9–12, 2023
Long-Term Responses With Loncastuximab Tesirine: Updated Results From LOTIS-2, the Pivotal Phase 2 Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Presentation will be accessible soon.
ASCO 2023 | POSTERJun 2–6, 2023
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7)
Presentation will be accessible soon.
AACR 2023 | POSTERApr 14–19, 2023
Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2
Presentation will be accessible soon.
AACR 2023 | POSTERApr 14–19, 2023
Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers
Presentation will be accessible soon.
AACR 2023 | POSTERApr 14–19, 2023
Discovery of plasma protein biomarkers associated with overall survival in R/R DLBCL patients treated with loncastuximab tesirine
Presentation will be accessible soon.
AACR 2023 | POSTERApr 14–19, 2023
A Phase 1/2 Randomized Study of Imvotamab Monotherapy and in Combination with Loncastuximab Tesirine in Relapsed/Refractory Non-Hodgkin Lymphomas
Collaboration
Collaboration
Presentation will be accessible soon.
ASH 2022 | POSTERDec 10–13, 2022
Identification of predictive biomarkers for response of R/R DLBCL patients treated with loncastuximab tesirine using low-pass whole-genome cell-free DNA sequencing (cfDNA-WGS)
Presentation will be accessible soon.
ASH 2022 | POSTERDec 10–13, 2022
Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data From the Open-Label, Multicenter, Phase 2 Study of Patients With R/R cHL
Presentation will be accessible soon.
ASH 2022 | POSTERDec 10–13, 2022
A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab in Previously Untreated Unfit/Frail Patients With DLBCL (LOTIS-9)
Presentation will be accessible soon.
ASH 2022 | POSTERDec 10–13, 2022
Real-world Outcomes in Relapse/Refractory DLBCL Patients Who Received Polatuzumab
Vedotin Plus Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide by Line of Therapy
Presentation will be accessible soon.
ASH 2022 | POSTERDec 10–13, 2022
Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties. “is not available at this time”
Presentation will be accessible soon.
ASH 2022 | POSTERDec 10–13, 2022
CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results From LOTIS-2 and Quantitative Systems Pharmacology Modeling
Presentation will be accessible soon.
ASH 2022 | POSTERDec 10–13, 2022
CD25, Soluble CD25, and CCL17 as Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients With R/R Classical HL
Presentation will be accessible soon.
ASH 2022 | ORAL PRESENTATIONDec 10–13, 2022
Real‐World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T‐cell Therapy Among Older Patients with
Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in US
Presentation will be accessible soon.
ASH 2022 | ORAL PRESENTATIONDec 10–13, 2022
ADCT-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia A Phase 1 Trial
Independent
Independent
Presentation will be accessible soon.
SOHO 2022 | ORAL PRESENTATIONSep 28–Oct 1, 2022
Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Presentation will be accessible soon.
SOHO 2022 | POSTERSep 28–Oct 1, 2022
Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
Presentation will be accessible soon.
SOHO 2022 | POSTERSep 28–Oct 1, 2022
Long-Term Survival Projections of Loncastuximab Tesirine‒Treated Patients in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Presentation will be accessible soon.
SOHO 2022 | POSTERSep 28–Oct 1, 2022
Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
Presentation will be accessible soon.
SOHO 2022 | POSTERSep 28–Oct 1, 2022
Health-Related Quality of Life and Tolerability in Patients With/Without Skin Toxicity During Loncastuximab Tesirine Treatment in a Phase 2 Clinical Trial (LOTIS-2)
Presentation will be accessible soon.
SOHO 2022 | POSTERSep 28–Oct 1, 2022
A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
Presentation will be accessible soon.
EHA 2022 | POSTERJun 9–17, 2022
Real-World characteristics and clinical outcomes in relapse/refractory diffuse large B-Cell lymphoma post CAR-T failure
Presentation will be accessible soon.
EHA 2022 | POSTERJun 9–17, 2022
Real-World characteristics and clinical outcomes in relapse/refractory diffuse large B-Cell lymphoma patients who received CAR-T therapy
Presentation will be accessible soon.
EHA 2022 | POSTERJun 9–17, 2022
Health-Related Quality of Life and Tolerability of Loncastuximab Tesirine in High-Risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)
Presentation will be accessible soon.
EHA 2022 | ORAL PRESENTATIONJun 9–17, 2022
Camidanlumab tesirine: updated efficacy and safety in an
open‐label, multicenter, phase 2 study of patients with relapsed
or refractory classical Hodgkin lymphoma (R/R cHL)
Presentation will be accessible soon.
ASCO 2022 | POSTERJun 3–7, 2022
Phase 3 Randomized Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL (LOTIS-5)
Presentation will be accessible soon.
ASCO 2022 | POSTERJun 3–7, 2022
First-in-Human, Phase 1, Open-Label, Dose-Escalation
Study of ADCT-901 as Monotherapy in Patients With Select
Advanced Solid Tumors
Presentation will be accessible soon.
ONS 2022 | POSTERApr 27–May 1, 2022
Characterization and Management of Cutaneous Reactions in Patients With Relapsed or Refractory
Diffuse Large B-Cell Lymphoma Treated With Loncastuximab Tesirine in the LOTIS-2 Trial
Presentation will be accessible soon.
ONS 2022 | POSTERApr 27–May 1, 2022
Onset, Duration, and Management of Edema and Effusion in Patients Treated With
Loncastuximab Tesirine for R/R DLBCL: Updated Results From the LOTIS-2 Clinical Trial
Presentation will be accessible soon.
AACR 2022 | POSTERApr 8–13, 2022
AXL as a therapeutic target in adenoid cystic carcinoma: preclinical evaluation of AXL targeting antibody-drug conjugate (ADCT-601)
Presentation will be accessible soon.
AACR 2022 | POSTERApr 8–13, 2022
Mechanistic studies investigating the synergistic combination of Loncastuximab Tesirine and Ibrutinib in pre-clinical models of B-Cell non-Hodgkin lymphoma
Presentation will be accessible soon.
AACR 2022 | POSTERApr 8–13, 2022
Effect of Camidanlumab Tesirine (Cami) as Monotherapy and in Combination With Pembrolizumab
(PEM) on the Immune Cell Profile in Patients With Selected Advanced Solid Tumors
Presentation will be accessible soon.
NCCN 2022 | POSTERMar 31–Apr 2, 2022
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)
Presentation will be accessible soon.
HOPA 2022 | POSTERMar 30–Apr 2, 2022
A Pooled Safety Analysis of Loncastuximab Tesirine in R/R DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
Presentation will be accessible soon.
ASH 2021 | POSTERDec 11–14, 2021
Clinical Characteristics and Responses of Patients With
Relapsed or Refractory High-Grade B-Cell Lymphoma Treated
With Loncastuximab Tesirine in the LOTIS-2 Clinical Trial
Presentation will be accessible soon.
ASH 2021 | ORAL PRESENTATIONDec 11–14, 2021
Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B‐Cell Lymphoma (LOTIS‐3)
Presentation will be accessible soon.
ASH 2021 | POSTERDec 11–14, 2021
Clinical Characteristics and Responses of Patients with Relapsed or Refractory High‐Grade B‐Cell Lymphoma Treated with Loncastuximab Tesirine in the LOTIS‐2 Clinical Trial
Presentation will be accessible soon.
AMCP Nexus 2021 | POSTEROct 19–22, 2021
Budget Impact Model for Loncastuximab Tesirine-lpyl in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Presentation will be accessible soon.
SOHO 2021 | POSTERSep 8–11, 2021
Incidence, onset, and management of edema and effusion in patients treated with loncastuximab tesirine for R/R DLBCL in the LOTIS clinical trial program
Presentation will be accessible soon.
SOHO 2021 | ORAL PRESENTATIONSep 8–11, 2021
LOTIS-2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-Cell lymphoma
Presentation will be accessible soon.
SOHO 2021 | ORAL PRESENTATIONSep 8–11, 2021
LOTIS-2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-Cell lymphoma
Presentation will be accessible soon.
SOHO 2021 | POSTERSep 8–11, 2021
Incidence, onset, and management of myelosuppression in patients treated with loncastuximab tesirine for R/R DLBCL in a pooled safety analysis
Presentation will be accessible soon.
ICML 2021 | POSTERJun 18–22, 2021
A Phase 2 randomized study of loncastuximab tesirine (Lonca) vs idelalisib in patients with relapsed or refractory (R/R) follicular lymphoma (FL) — LOTIS-6
Presentation will be accessible soon.
ICML 2021 | POSTERJun 18–22, 2021
A Phase 3 randomized study of loncastuximab tesirine plus rituximab vs immunochemotherapy in patients with relapsed/refractory diffuse large B-Cell lymphoma — LOTIS-5
Presentation will be accessible soon.
ICML 2021 | POSTERJun 18–22, 2021
LOTIS-2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed
or refractory diffuse large B-Cell lymphoma
Presentation will be accessible soon.
ICML 2021 | ORAL PRESENTATIONJun 18–22, 2021
Camidanlumab tesirine efficacy and safety in an open-label, multicenter, Phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Presentation will be accessible soon.
ICML 2021 | POSTERJun 18–22, 2021
Clinical activity of loncastuximab tesirine plus ibrutinib in non-Hodgkin lymphoma: Updated LOTIS-3 Phase 1 results
Presentation will be accessible soon.
EHA 2021-2012 | POSTERJun 9, 2021–Jun 17, 2012
Duration of Response to Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B-cell Lymphoma by Demographic and Clinical Characteristics: Subgroup Analyses from LOTIS-2
Presentation will be accessible soon.
EHA 2021-2012 | POSTERJun 9, 2021–Jun 17, 2012
CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO RECEIVED ≥3 LINES OF THERAPIES
Presentation will be accessible soon.
ASCO 2021 | POSTERJun 4–8, 2021
Phase 3 Randomized Study of Lonca plus Rituximab versus Immunochemotherapy in Patients with RR DLBCL LOTIS
Presentation will be accessible soon.
ASCO 2021 | POSTERJun 4–8, 2021
Duration of Response to Lonca RR DLBCL by Demographic Subgroup Analysis from LOTIS
Presentation will be accessible soon.
ASCO 2021 | POSTERJun 4–8, 2021
A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate Camidanlumab Tesirine (Cami) as Monotherapy in Patients with Advanced Solid Tumors
Presentation will be accessible soon.
AACR 2021 | POSTERApr 10–15, 2021
Integrated Population Modeling of Loncastuximab Tesirine (Lonca) Exposure in B-cell Non-Hodgkin Lymphoma (B-NHL)
Presentation will be accessible soon.
AACR 2021 | POSTERApr 10–15, 2021
Relationship Between Exposure and Safety/Efficacy of Loncastuximab Tesirine in B-cell Non-Hodgkin Lymphoma
Presentation will be accessible soon.
ASH 2020 | POSTERDec 5–8, 2020
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Presentation will be accessible soon.
ASH 2020 | POSTERDec 5–8, 2020
Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and
Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma
Presentation will be accessible soon.
ASH 2020 | POSTERDec 5–8, 2020
Analysis of ADCT-602 Pre-Clinical Activity in B-Cell Lymphoma Models and
Identification of Potential Biomarkers for Its Activity
Presentation will be accessible soon.
ASH 2020 | POSTERDec 5–8, 2020
Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a
Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients
With Relapsed or Refractory Hodgkin Lymphoma
Presentation will be accessible soon.
ASH 2020 | POSTERDec 5–8, 2020
Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with
Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models
Presentation will be accessible soon.
ASH 2020 | POSTERDec 5–8, 2020
Pharmacokinetic and Pharmacodynamic Correlates From the Phase 1
Study of Camidanlumab Tesirine (Cami) in Patients With Relapsed or
Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Presentation will be accessible soon.
SITC 2020 | POSTERNov 11–14, 2020
A Tregs-depleting CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers
Presentation will be accessible soon.
ESMO 2020 | POSTERSep 19–21, 2020
First-in-Human Study of Camidanlumab Tesirine (ADCT-301, Cami), an anti-CD25 Targeted Therapy in Patients (Pts) with Advanced Solid Tumors: Pharmacokinetics (PK) and Biomarker Evaluation
Presentation will be accessible soon.
EHA 2020 | ORAL PRESENTATIONJun 11–21, 2020
Initial Results of a Phase 2 Study of Loncastuximab Tesirine, a Novel
Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients
With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Presentation will be accessible soon.
EHA 2020 | POSTERJun 11–21, 2020
Interim results of a phase 1/2 study of loncastuximab tesirine (Lonca) combined with ibrutinib in advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL)
Presentation will be accessible soon.
ASH 2019 | PRESENTATIONDec 7–10, 2019
Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Presentation will be accessible soon.
SITC 2019 | POSTERNov 7–10, 2019
Pre-clinical characterization of the mechanism of action of a CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting regulatory T cells in solid cancers
Presentation will be accessible soon.
ESMO 2019 | POSTERSep 27–Oct 1, 2019
A Phase 1, Open-label, Dose-Escalation Study to Evaluate the Safety,
Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in
Patients with Advanced Solid Tumors
Presentation will be accessible soon.
ICML 2019 | ORAL PRESENTATIONJun 18–23, 2019
Analysis of Efficacy and Safety of Loncastuximab Tesirine
(ADCT-402) by Demographic and Clinical Characteristics in
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Presentation will be accessible soon.
ICML 2019 | ORAL PRESENTATIONJun 18–23, 2019
The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT 402)
Targeting CD19 Shows Strong in vitro Anti-Lymphoma Activity Both As Single
Agents and in Combination
Presentation will be accessible soon.
ICML 2019 | ORAL PRESENTATIONJun 18–23, 2019
Analysis of Clinical Determinants Driving Safety and Efficacy
of Camidanlumab Tesirine (ADCT-301, Cami) in
Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
Presentation will be accessible soon.
ICML 2019 | POSTERJun 18–23, 2019
The anti-CD25 antibody-drug conjugate camidanlumab tesirine (ADCT-301) presents a strong preclinical activity both as single agent and in combination in lymphoma cell lines
Presentation will be accessible soon.
AACR 2019 | POSTERMar 29–Apr 3, 2019
Pre-clinical characterization of 3A4-PL1601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) directed against KAAG1-expressing malignancies
Presentation will be accessible soon.
ASH 2018 | PRESENTATIONDec 1–4, 2018
Phase 1 Study of ADCT-301 (Camidanlumab Tesirine), a Novel
Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in
Relapsed/Refractory Classical Hodgkin Lymphoma
Presentation will be accessible soon.
SITC 2018 | POSTERNov 9–11, 2018
A CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate shows potent anti-tumor activity in pre-clinical models of solid tumors either alone or in combination with a PD-1 inhibitor
Presentation will be accessible soon.
AACR 2018 | POSTERApr 14–18, 2018
Pre-clinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors
Presentation will be accessible soon.
AACR 2018 | POSTERApr 14–18, 2018
ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors
Presentation will be accessible soon.
ASH 2017 | POSTERDec 9–12, 2017
Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2
Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Presentation will be accessible soon.
ASH 2017 | POSTERDec 9–12, 2017
Results from an Ongoing Phase 1 Study Indicate ADCT-301 (Camidanlumab Tesirine) Is Well Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia
Presentation will be accessible soon.
AACR 2017 | POSTERApr 1–5, 2017
Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, no. 51 a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies
Presentation will be accessible soon.
ASH 2016 | POSTERDec 3–6, 2016
ADCT-602 (hLL2-cys-PBD), a new site-specifically conjugated, pyrrolobenzodiazepine (PBD) dimer-based antibody drug conjugate (ADC) targeting CD22-expressing B-cell malignancies
Presentation will be accessible soon.
ASCO 2016 | POSTERJun 3–7, 2016
A phase 1 dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-Cell lineage non-Hodgkin lymphoma (B-NHL)
Presentation will be accessible soon.
AACR 2015 | POSTERApr 18–22, 2015
Pre-clinical Activity of hLL2-PBD, a Novel Anti-CD22 Antibody-Pyrrolobenzodiazepine (PBD) Conjugate in Models of Non-Hodgkin Lymphoma
Presentation will be accessible soon.
Contact ADC Therapeutics
Report Adverse Reactions or Product Complaints
To report suspected adverse events or product complaints, please call us at 1-855-690-0340 and select prompt 1. You may also call the FDA at 1-800-FDA-1088 or report suspected adverse events at www.fda.gov/medwatch.
